Core Insights - Aclarion, Inc. is expanding the access of its Nociscan technology across multiple sites in New York and New Jersey to address the growing demand for chronic low back pain solutions [1][2] - The expansion is supported by enhanced remote operations capabilities and increased availability of Magnetic Resonance Spectroscopy (MRS) within RadNet [1][2] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary AI algorithms to assist physicians in identifying chronic low back pain locations [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][5] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge [4] - The Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][5] Strategic Partnerships - Lenox Hill Radiology operates 79 locations in New York and has adopted Nociscan to enhance access for leading spine physicians [2][3] - New Jersey Imaging Network, with 33 locations, was the first in NJ to adopt Nociscan, facilitating support for local and out-of-market referrals [3]
Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey